2020
- DRG´s headquater DRG International, Inc., is celebrating 50th anniversary!
2019
- DRG is certified according to EN ISO 13485:2016
- DRG won a trophy at the French exibition JIB in Paris. The tophy was announced for "Processes and Technological Advances for Biological Analysis with Hepcidin 25 (bioactive) on DRG:HYBRiD-XL".
- Salivary Hepcidin assay has been nominated for SelectScience Scientists' Choice Awards for Best New Clinical Product of 2018!
- Acquisition of fertility test production of Bioserv Diagnostics GmbH (Germany): Anti Sperm Ab (serum), Anti Sperm Ab (seminal), Anti Ovarian Ab, Anti Zona Pellucida Ab ELISAs
2018
- The unique assay Salivary Hepcidin was presented to the market
- PSA was launched for the instrument DRG:HYBRiD-XL
2017
- DRG launched 3 new assays for DRG:HYBRiD-XL:
Beta hCG, Free Estriol and Tumor Marker CA72-4
2016
- DRG´s DRG:HYBRiD-XL is Winner or the German Design Award 2016, category "Special Mention"
- Two new assays for DRG:HYBRiD-XL are launched: AFP, Calprotectin (Stool)
- DRG launched a new Salivary ELISA: Progesterone HS
2015
- DRG´s DRG:HYBRiD-XL is nominee for the German Design Award.
- 6 new assays for DRG:HYBRiD-XL are launched: CRP-HS, Hepcidin 25 (bioactive), Insulin, FSH, LH, Prolactin
- DRG promotes the new DHT-optimized ELISA at MEDICA
2014
- DRG is Winner of MDEA (Medical Design Excellence Awards) 2014 Bronze Award.
- Launch of 12 new assays for automated Analyzer DRG:HYBRiD-XL: Androstenedione, Cystatin C, DHEA, DHEA-S, d-Dimer, Free Testosterone, HbA1c and Thyroid assays TSH, T3, T4, free T3, free T4
2013
- First sales of automated Analyzer DRG:HYBRiD-XL at MEDICA 2013 together with 9 assays: 17-OH Progesterone, 25-OH Vitamin D (total), Aldosterone, CRP, Cortisol, Estradiol, Progesterone, Renin (activ) and Testosterone.
- First training sessions on DRG:HYBRiD-XL for technicians and sales staff with participants from Algeria, UK, Indonesia, Saudi Arabia, Uzbekistan, Venezuela and UAE.
2012
- Development and introduction of new test kits: 25-OH Vitamin D total, Aldosterone, Estrone Salivary and Hepcidin bioactive ELISA
- Launch of the automated analyzer DRG:HYBRiD-XL to the market at AACC 2012
2011
- Extention to the building of DRG Instruments in Marburg with new 730 square meter building.
September 2nd 2011, the new building is opened officially with a big party.
- Development and introduction of a new test kit: Amyloid beta (1-40) serum ELISA
2010
- Celebration of 40 Years of Excellence (1970 - 2010)
- Development and introduction of new test kits: Renin (active), Amyloid beta Auto-Ab (Serum), L1-CAM, CRYPTO-1, Afamin, Cyr61, NOV ELISA
- DRG acquires DIMA Diagnostica from bioMérieux
2009
- Introduction of the world´s the first Hepcidin Test Kit
- DRG developed a Connective Tissue Growth Factor (CTGF) Elisa which allows for clinical-value measurement in serum of CTGF in patients with chronic Hepatitis C Virus (HCV) and chronic liver disease
- Vitamin Assays was added to the DRG product line
- The new and unique closed system DRG:HYBRiD.XL was presented at MEDICA 2009 in Duesseldorf -
A fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry
2008
- DRG received two U.S. patents for its Hepcidin Test Kit
- Start of the development of a closed system, our DRG:HYBRiD.XL, a fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry.
- DRG gained U.S. FDA approval for DRG's 17α-OH Progesterone Saliva kit (SLV-3140) for use worldwide
- DRG developed a new Preeclampsia Test (PLGF ELISA) to determine the occurrence of preeclampsia in pregnant women. Preeclampsia, a multi-systemic disorder affecting mother and child at the end of the second trimester, is a major cause of maternal and perinatal mortality worldwide
2007
- Launch of a new CHROMagar medium targeted to detect the Vancomycin Resistant Enterococcus faecalis and faecium and to differentiate them from the other bacteria
- DRG announced its newest line of Veterinary ELISAs, including Canine, Equine, Rat and Lab animals
- Introduction of a new Avian Influenza A ELISA Kit
2006
- Launch of the Neonatal Screening PKU (Phenylketonuria). PKU is one of the most prevalent hereditary diseases in the metabolism of amino acids
- Launch of the new ELISA PAPP-A
2005
- DRG launched its Platinum Standard Tumor Markers
2004
- Development of TUMOR MARKERS, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra 21-1
- Introduction of the Corticosterone & Estrone ELISAs
2003
- Development and introduction of the world´s first Assay for measurement of Hepcidin
- DRG aquired Novum-Diagnostics, Dietzenbach, and took over the production of more than 70 ELISAs for infectious diseases in DRG-Novum Branch lab
2002
- Development and introduction of various Saliva kits including DHEA Saliva
2001
- Dade Behring Technology transferred to DRG production of C5a and PAP - ELISAs
|
|
2000
- Development and introduction of IGF1, IL-6, Cortisol- Saliva and Androstenedione ELISAs
- Certification of QM-System EN ISO 9001: 1994 DNV
1999
- Development and introduction of Insulin, PAPP-A, TGFß 2 ELISAs
1998
- DRG moved to the New Building in Marburg
- 25 years DRG Instruments GmbH, Marburg, Germany
1997
- Development and introduction of Leptin, TGFß 1, and ß-HCG ELISAs
1996
- Development and introduction of Free Estriol ELISA
1995
- Development and introduction of the first worldwide non-radioactive C-Peptide and Proinsulin Assays
1994
- Development and introduction of of DHEA-S, Progesterone, Testosterone, PMSG, ß-HCG ELISAs
- DRG Diagnostics Branch Office Berlin, Germany
1993
- DRG Techsystems founded in Moscow, Russia
- Developed and introduced 17-OH-Progesterone ELISA
1992
- DRG Spol. s.r.o., founded in Brno, Czechoslovakia (Czech Republic)
- Developed and Introduced AFP, HCG, FSH, Prolactin and LH
1991
- DRG Biomed founded in St. Petersburg, Russia
- Market entry of first Neonatal DRG Elisa: HPL
1990
- DRG MEDTEK founded in Warsaw, Poland
- Started R&D and production of ELISAs in Marburg, Germany
1988
- DRG AG Zurich Switzerland
1985
- DRG began in-house R&D Operations
1982
- West and East Europe Expansion
1981
- Entered Middle East Markets: Saudi Arabia, Kuwait and Iran
- St. Jude Medical Bi-Leaflet Mechanical Heart Valve introduced to European Cardiac Surgery Market by DRG International
1975
- DRG´s first participation at MEDICA, Düsseldorf, Germany
1974
- DRG Instruments GmbH moved to Marburg, Germany
1973
- Distribution of RIA's in Germany
- DRG Instruments GmbH, Germany, founded in Munich
1970
- DRG enters market in Europe, USSR, Poland, Yugoslavia
- DRG International Inc. (NJ) founded by Dr. C.E. Geacintov
|
